Introduction
============

Liver cancer, primarily hepatocellular carcinoma (HCC), is the third most common cause of mortality from cancer worldwide. Diagnostic and treatment strategies for liver cancer have improved, with hepatic resection being the preferred first-line treatment ([@b1-ol-0-0-5919],[@b2-ol-0-0-5919]). Patients\' safety is paramount when performing hepatic surgery, although postoperative mortality occasionally occurs. Therefore, accurate assessment of hepatic functional reserve is important, particularly for hepatitis B virus (HBV)-related HCC patients, since they often possess impaired livers.

Hepatic functional reserve is determined by the quality and quantity of liver cells. The Child-Pugh score (CPS) is widely used to assess the quality of the liver, and hepatic surgeons frequently use it to select HCC patients for resection. The CPS is calculated by five parameters: Presence or absence of encephalopathy, degree of ascites, total serum bilirubin, albumin concentration and prothrombin time. According to the total point score, CPS can be divided into grade A (5--6 points), B (7--9 points) or C (10--15 points) ([@b3-ol-0-0-5919]). In clinical practice, the majority of HCC patients who are eligible for resection are Child-Pugh classification A patients ([@b2-ol-0-0-5919],[@b4-ol-0-0-5919]). However, postoperative liver dysfunction (PLD) and postoperative mortality occasionally occur in Child-Pugh A patients. It appears that the Child-Pugh classification alone may be unreliable for predicting postoperative outcomes.

To overcome the possible limitations of Child-Pugh classification for predicting postoperative outcomes, liver computed tomography (CT) volumetry has been used to assist in the assessment of hepatic functional reserve in recent years, particularly when selecting HCC patients for major hepatic resection ([@b5-ol-0-0-5919]). Future liver remnant (FLR) volume measured preoperatively by three-dimensional CT reconstruction can accurately reflect the size of the remnant liver ([@b6-ol-0-0-5919],[@b7-ol-0-0-5919]). Patients with a smaller FLR are at a higher risk of developing PLD or postoperative liver failure ([@b8-ol-0-0-5919]--[@b10-ol-0-0-5919]). The main limitation of CT volumetry is the fact that volumetric assessment of the remnant liver does not take into account the quality of the liver parenchyma, and therefore is not reliable in predicting PLD in patients with impaired livers. The safe limit of FLR ranges from 35 to 50% in patients with chronic liver diseases ([@b2-ol-0-0-5919],[@b9-ol-0-0-5919],[@b11-ol-0-0-5919]). To improve the prediction of postoperative outcomes, CT volumetry should be complemented with a method that assesses hepatic function.

In the present study, the CPS was used to assess the quality of the remnant liver, and the standardized FLR (sFLR) measurement was used to evaluate the size of the remnant liver. In addition, risk factors were investigated in relation to PLD in patients with HBV-related HCC. The CPS was combined with the sFLR measurement in an attempt to predict PLD more accurately.

Patients and methods
====================

### Patients

Between March 2014 and February 2015, 70 patients with HCC underwent three-dimensional CT reconstruction for the preoperative measurement of remnant liver volume prior to hepatectomy at the Department of Hepatobiliary Surgery, Xiangya Hospital, Central South University (Changsha, Hunan, China). Of these 70 patients, 1 patient who had undergone hepatectomy for HCC within 1 year of the present study and 8 patients who were negative for hepatitis B surface antigen were excluded. Ultimately, 61 patients with chronic hepatitis B were included. None of these patients had biliary obstruction prior to surgery or evidence of hepatitis C virus (HCV)-specific antibodies or alcoholic cirrhosis. All surgery was performed through open hepatectomy by a single team of surgeons. Informed consent for the clinical study was obtained from all patients, and the present study was approved by the Institutional Review Board of Central South University. Postoperative liver dysfunction was defined as a prothrombin time of \>18 sec (normal range, 10--14 sec) or a peak serum bilirubin level of \>51.3 µmol/l (normal range, 5.1--17.1 µmol/l) ([@b12-ol-0-0-5919],[@b13-ol-0-0-5919]) for 7 days after surgery.

### Liver volumetry and calculation of the FLR

Prior to surgery, all patients underwent a contrast-enhanced CT angiography scan with a slice thickness of 0.8 mm. Automated volumetry was performed for three-dimensional reconstruction of the liver using medical image analysis software (Myrian^®^; Intrasense S.A.S., Montpellier, France) and the results were modified by manual contour tracing of the hepatic contour following automated reconstruction. The gall bladder, hepatic inferior vena cava and main branches of the intrahepatic vascular structures were excluded from the reconstructional volume calculation, but the biliary structures were included. Preoperative virtual hepatic resection was performed according to the size and location of the tumors, which were evaluated by two experienced hepatic surgeons. The liver reconstruction and virtual hepatic resection are shown in [Fig. 1](#f1-ol-0-0-5919){ref-type="fig"}.

The total liver volume and FLR volume were calculated using image analysis software. The percentage of FLR was calculated as the sFLR using the following equation: sFLR=FLR/standardized liver volume (SLV). The SLV was calculated using the following equation: SLV (cm^3^)=706.2 × body surface area (BSA; m^2^)+2.4 ([@b14-ol-0-0-5919]). The BSA was calculated using an equation that includes bodyweight and height: BSA (m^2^)=0.00607 × height (cm)+0.0127 × weight (kg)-0.0698 for men; and BSA (m^2^)=0.00586 × height (cm)+0.0126 × weight (kg)-0.0461 for women. The sFLR/CPS was calculated as a combinatorial measure of sFLR and CPS.

### Statistical analysis

Continuous variables are expressed as medians (range) and were compared using the Mann-Whitney U test. Discrete variables were compared using the χ^2^ test or Fisher\'s exact test. Univariate analysis and multivariate logistic regression analysis were performed to identify risk factors associated with PLD. Correlation analyses were performed using Pearson\'s correlation coefficient. The cut-off values for the occurrence of PLD were determined by receiver operating characteristic (ROC) curve analysis. Statistical analyses were performed using SPSS 17.0 (SPSS, Chicago, IL, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Clinicopathological characteristics and modalities of hepatic resection

A total of 61 patients were enrolled in the present study, comprising 52 men and 9 women, with a median age of 51 years (range, 21--70 years). The surgical modalities were as follows: 18 patients underwent hemihepatectomy (right hemihepatectomy in 14 and left hemihepatectomy in 4), 17 patients underwent bisectionectomy (right anterior sectionectomy in 4, right posterior sectionectomy in 6 and left lateral sectionectomy in 7) and 26 patients underwent partial resection. None of the patients were allergic to anesthesia or experienced cardiac arrest during surgery. Postoperative pathological examinations revealed that 42 patients (68.9%) had liver cirrhosis.

### Postoperative liver dysfunction and complications

In total, 18 of the 61 patients (29.5%) developed PLD. Only 1 patient (1.6%) succumbed to intra-abdominal bleeding 15 days after surgery. Of the 61 patients, 19 (31.1%) developed one or more complications after surgery and 11 (18.0%) developed postoperative infection, which was the most common complication. The following additional complications were observed: Pleural effusions in 5 patients (8.2%), bile leakage in 3 patients (4.9%), postoperative hemorrhage in 2 patients (3.3%) and temporary atrial fibrillation in 1 patient (1.6%).

### Child-Pugh classification and postoperative liver dysfunction

According to the Child-Pugh classification criteria, 58 patients were of Child-Pugh grade A (with a CPS of 5 in 42 patients and a CPS of 6 in 16 patients) and 3 patients were of Child-Pugh grade B (with a CPS of 7 in 2 patients and a CPS of 8 in 1 patient). A total of 16 of the 58 (27.6%) Child-Pugh A patients developed PLD, and 2 of the 3 Child-Pugh B patients developed PLD. Of the 58 Child-Pugh A patients, 8 of the 42 (19.0%) patients with a CPS of 5 developed PLD and 8 of the 16 (50.0%) patients with a CPS of 6 developed PLD. This difference was significant (Fisher\'s exact test, P=0.026), indicating that the incidence of PLD for patients with a CPS of 6 was higher than that for patients with a CPS of 5.

### Prothrombin time and sFLR are independent risk factors for postoperative liver dysfunction

The univariate analysis revealed no differences between the two groups in terms of age, body mass index, surgical duration, albumin, total bilirubin, alanine aminotransferase, aspartate aminotransferase, blood sugar, cholesterol, platelet count, presence of inflow occlusion, presence of blood transfusion, presence of hepatitis B e antigen, presence of HBV-DNA or presence of liver cirrhosis (P\>0.05; [Table I](#tI-ol-0-0-5919){ref-type="table"}). However, tumor diameter (P=0.043), blood loss (P=0.015), prothrombin time (PT) (P=0.007), CPS (P=0.007) and sFLR (P\<0.001) were significantly different between the two groups ([Table I](#tI-ol-0-0-5919){ref-type="table"}).

A multivariate logistic regression analysis was performed to identify risk factors for PLD. Age, body mass index, operating time, albumin, total bilirubin, alanine aminotransferase, blood sugar, cholesterol, platelet count, inflow occlusion, positive HBeAg, liver cirrhosis, PT, blood loss, tumor diameter and sFLR were entered into the multivariate logistic regression model to avoid collinearity ([Table II](#tII-ol-0-0-5919){ref-type="table"}). A prolonged PT and small sFLR were identified as significant independent predictors of PLD ([Table II](#tII-ol-0-0-5919){ref-type="table"}).

### sFLR and sFLR/CPS correlate with postoperative peak bilirubin levels and postoperative peak prothrombin time

Pearson\'s correlation analysis revealed that the postoperative peak bilirubin level had a stronger negative correlation with sFLR/CPS (P\<0.0001, r=−0.547) than with sFLR (P\<0.0001, r=−0.488) ([Fig. 2](#f2-ol-0-0-5919){ref-type="fig"}). The postoperative peak PT had a stronger negative correlation with sFLR/CPS (P\<0.0001, r=−0.541) than with sFLR (P\<0.0001, r=−0.517) ([Fig. 2](#f2-ol-0-0-5919){ref-type="fig"}).

### sFLR and sFLR/CPS are predictors of postoperative liver dysfunction

ROC curve analysis revealed that the cut-off value of sFLR for predicting PLD was 54.5%, with 81.4% sensitivity and 77.8% specificity ([Fig. 3](#f3-ol-0-0-5919){ref-type="fig"}). In total, 14 of the 22 (63.6%) patients with an sFLR \<54.5% developed PLD, compared with 4 of the 39 (10.3%) patients with a larger sFLR. This difference was statistically significant (χ^2^=19.268, P\<0.001). The cut-off value of sFLR/CPS for predicting PLD was 0.0916, with 86.0% sensitivity and 77.8% specificity ([Fig. 3](#f3-ol-0-0-5919){ref-type="fig"}). Of the 20 patients with an sFLR/CPS of \<0.0916, 14 (70.0%) developed PLD compared with 4 of 41 (9.8%) patients with a higher sFLR/CPS, and this difference was statistically significant (χ^2^=23.455, P\<0.001). This result indicates that sFLR/CPS was a more useful predictor of PLD in HBV-related HCC patients following hepatic resection compared with sFLR alone.

sFLR and CPS are linked to postoperative liver dysfunction. The distribution of PLD in patients with different CPSs and different sFLRs is demonstrated in [Fig. 4](#f4-ol-0-0-5919){ref-type="fig"}. According to the distribution of PLD, the majority of patients with a CPS of 5 who developed PLD had an sFLR of \<43%, and the majority of the patients with a CPS of 6 who developed PLD had an sFLR of \<54%.

Discussion
==========

In the present study, the incidence of PLD among Child-Pugh A patients was revealed to be significantly higher in patients with a CPS of 6 than in those patients with a CPS of 5 (P\<0.05), indicating that hepatic function may not be the same for all HCC patients with Child-Pugh A. For a number of years, the selection of HCC patients for hepatic resection has been based on the Child-Pugh classification ([@b15-ol-0-0-5919]); however, flaws in this classification system have been described recently ([@b16-ol-0-0-5919]--[@b18-ol-0-0-5919]). First, a number of the variables included in the Child-Pugh classification are interrelated (e.g., ascites and serum albumin levels). Second, the grading of ascites and encephalopathy is subjective. Third, the cut-off value for each variable is selected empirically. Finally, the Child-Pugh classification system does not offer a wide degree of discrimination for HCC patients undergoing hepatic resection, the majority of whom have Child-Pugh A disease. Certain studies have reported the unreliability of the Child-Pugh classification system for predicting postoperative outcomes ([@b17-ol-0-0-5919],[@b19-ol-0-0-5919]--[@b21-ol-0-0-5919]). The data from the present study revealed that heterogeneity may exist in Child-Pugh A patients. There is a requirement to identify 'good risk' and 'poor risk' Child-Pugh A patients. Furthermore, even for multiple patients with a given CPS, different postoperative outcomes were observed in the present study, possibly since the remnant liver volume varied for these patients.

More recently, with the advancement of three-dimensional imaging technologies, the importance of preoperative volumetric analysis for major hepatic resection has been increasingly emphasized ([@b5-ol-0-0-5919],[@b22-ol-0-0-5919]). Previous studies have demonstrated that a small FLR is associated with worse postoperative hepatic function ([@b23-ol-0-0-5919],[@b24-ol-0-0-5919]). As in previous studies, the findings from the present study suggested that sFLR is an independent risk factor for PLD. However, there were patients in the present study who had a small FLR but did not develop PLD, indicating that FLR may not be the only factor that affects postoperative outcomes. There is little doubt that hepatic function also plays an important role in predicting postoperative outcomes ([@b25-ol-0-0-5919],[@b26-ol-0-0-5919]). Theoretically, with a higher CPS, a larger FLR is required to avoid PLD. Judging from the distribution of PLD ([Fig. 4](#f4-ol-0-0-5919){ref-type="fig"}), data from the present study revealed that to avoid PLD in HBV-related HCC patients following hepatic resection, an sFLR of 43% is relatively safe when the CPS is 5, and an sFLR of 54% is relatively safe when the CPS is 6. It is predicted that a higher sFLR is required when the CPS is 7 or 8. These results require testing and verifying with more cases in clinical practice, in particular with more patients with a CPS of 7 or 8.

In addition, by using sFLR/CPS as a combinatorial measure of sFLR and CPS, it was revealed that sFLR/CPS showed a stronger negative correlation with postoperative peak bilirubin levels and postoperative peak PT than sFLR, and ROC curve analysis revealed that the cut-off value of sFLR/CPS could predict PLD more accurately than sFLR. This indicates that sFLR/CPS is a more accurate predictor of postoperative hepatic function than sFLR.

The present study has a number of limitations. First, the time span of the study was short, and all the subjects were enrolled from a single study center. In addition, the study focused on HCC patients infected with HBV. It is possible that the results do not apply to HCC patients in other countries where HCV infection or alcoholic cirrhosis may be the most common cause of HCC. Therefore, these study results require validation in Western and Asia-Pacific patient populations. Finally, no evaluation was performed of the correlations between the preoperative liver volumetry and the weight of the resected specimen.

In conclusion, the combination of sFLR and CPS was identified as aiding a more accurate assessment of hepatic functional reserve and improving prevention of the occurrence of postoperative liver dysfunction compared with either CPS or sFLR alone.
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![Three-dimensional reconstruction and virtual hepatic resection. Red, hepatic artery; pink, tumor; green, hepatic vein; blue, portal vein; light brown, hepatic parenchyma. (A) Computed tomography scan of the right hepatocellular carcinoma. (B) Volume of the reconstructional liver. (C) Virtual hepatic resection prior to surgery. (D) Remnant liver volume after virtual hepatic resection.](ol-13-05-3631-g00){#f1-ol-0-0-5919}

![Graphs showing strong negative correlations between (A) sFLR and postoperative peak bilirubin levels, (B) sFLR/CPS and postoperative peak bilirubin levels, (C) sFLR and postoperative peak PT, and (D) sFLR/CPS and postoperative peak PT. sFLR, standardized future liver remnant; CPS, Child-Pugh score; PT, prothrombin time.](ol-13-05-3631-g01){#f2-ol-0-0-5919}

![Receiver operating characteristic curve analysis of sFLR and sFLR/CPS to predict postoperative liver dysfunction. A 54.5% cut-off value for sFLR was identified (area under the curve, 0.820; P\<0.001; 95% confidence interval, 0.712--0.927). A 0.0916 cut-off value for sFLR/CPS was identified (area under the curve, 0.860; P\<0.001; 95% confidence interval, 0.766--0.954). sFLR, standardized future liver remnant; CPS, Child-Pugh score.](ol-13-05-3631-g02){#f3-ol-0-0-5919}

![Distribution of PLD in patients with different Child-Pugh scores and different sFLRs. PLD, postoperative liver dysfunction; sFLR, standardized future liver remnant.](ol-13-05-3631-g03){#f4-ol-0-0-5919}

###### 

Univariate analysis of risk factors of postoperative liver dysfunction.

                                                                  Postoperative liver dysfunction                          
  --------------------------------------------------------------- --------------------------------- ---------------------- ----------------------------------------------------
  Age, years                                                      49.0 (26--65)                     51.0 (21--70)          0.716
  BMI, kg/m2^[a](#tfn1-ol-0-0-5919){ref-type="table-fn"}^         22.1 (17.9--30.4)                 21.1 (17.6--30.5)      0.211
  Tumor diameter, cm                                              8.0 (2.3--14.7)                   4.4 (2.0--12.6)        0.043
  Operating time, min                                             156.5 (90--280)                   135.0 (70--260)        0.143
  Blood loss, ml                                                  600.0 (100--3000)                 400.0 (40--1200)       0.015
  ALB, g/l                                                        40.8 (30.6--53.3)                 40.8 (34.7--48.5)      0.482
  Total bilirubin, µmol/l                                         14.2 (6.5--27.8)                  11.8 (4.0--30.2)       0.209
  ALT, U/l                                                        45.8 (16.5--140.9)                36.7 (9.4--142.8)      0.060
  AST, U/l                                                        46.9 (17.1--76.9)                 37.0 (13.4--117.2)     0.056
  Blood sugar, mmol/l                                             5.2 (4.1--7.4)                    5.0 (3.7--8.4)         0.496
  Cholesterol, mmol/l                                             4.2 (1.7--6.1)                    4.2 (3.0--5.8)         0.289
  PT, sec                                                         13.9 (11.9--16.4)                 13.2 (11.5--15.0)      0.007
  Platelet count, ×10^9^/l                                        149.5 (32--247)                   129.0 (48--437)        0.664
  Child-Pugh score                                                6.0 (5--8)                        5.0 (5--7)             0.007
  sFLR                                                            0.501 (0.352--0.794)              0.755 (0.361--1.101)   \<0.001
  Inflow occlusion^[b](#tfn2-ol-0-0-5919){ref-type="table-fn"}^                                                            0.134^[c](#tfn3-ol-0-0-5919){ref-type="table-fn"}^
    Yes                                                           10                                15                     
    No                                                            8                                 28                     
  Blood transfusion                                                                                                        0.429^[d](#tfn3-ol-0-0-5919){ref-type="table-fn"}^
    Yes                                                           4                                 5                      
    No                                                            14                                38                     
  HBeAg                                                                                                                    0.411^[d](#tfn4-ol-0-0-5919){ref-type="table-fn"}^
    Positive                                                      3                                 4                      
    Negative                                                      15                                39                     
  HBV-DNA                                                                                                                  0.301^[c](#tfn3-ol-0-0-5919){ref-type="table-fn"}^
    Positive (\>500/copies)                                       13                                25                     
    Negative (\<500/copies)                                       5                                 18                     
  Liver cirrhosis                                                                                                          0.811^[c](#tfn3-ol-0-0-5919){ref-type="table-fn"}^
    Yes                                                           12                                30                     
    No                                                            6                                 13                     

BMI, body mass index, BMI (kg/m^2^)=weight (kg)/height (m^2^)

Patients received inflow occlusion during surgeries via the Pringle maneuver

Pearson χ^2^

Fisher\'s exact test. ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PT, prothrombin time; sFLR, standardized future liver remnant; HBeAg, hepatitis B e antigen; HBV-DNA, hepatitis B virus DNA.

###### 

Multivariate logistic regression analysis for risk factors of postoperative liver dysfunction.

                                                                95% confidence                    
  ------------------------------------------------------------- ---------------- ---------------- -------
  Age \>60 years                                                9.643            0.533--174.458   0.125
  BMI \>25 kg/m^2[a](#tfn5-ol-0-0-5919){ref-type="table-fn"}^   1.561            0.130--18.736    0.725
  Tumor diameter \>5 cm                                         5.687            0.283--114.154   0.256
  Operating time \>150 min                                      4.342            0.463--40.699    0.198
  Blood loss \>400 ml                                           2.190            0.238--20.122    0.489
  ALB \<40 g/l                                                  2.409            0.224--25.881    0.468
  Total bilirubin \>17.1 µmol/l                                 7.434            0.384--143.988   0.185
  ALT \>40 U/l                                                  4.106            0.283--59.634    0.301
  Blood sugar \>6.1 mmol/l                                      1.487            0.052--42.484    0.817
  Cholesterol \>4.2 mmol/l                                      1.734            0.140--21.476    0.668
  PT \>13.3 sec                                                 26.697           2.366--301.169   0.008
  Platelet count \<100×10^9^/l                                  0.259            0.012--5.805     0.394
  sFLR\<0.55                                                    27.014           1.356--538.118   0.031
  Inflow occlusion                                              17.864           0.865--368.948   0.062
  Positive HBeAg                                                11.419           0.149--877.696   0.272
  Liver cirrhosis                                               10.073           0.511--198.729   0.129

BMI, body mass index, BMI (kg/m^2^)=weight (kg)/height (m^2^); ALB, albumin; ALT, alanine aminotransferase; PT, prothrombin time; sFLR, standardized future liver remnant; HBeAg, hepatitis B e antigen.
